Trends in Drug-Related Hospitalisations in Australia, 2003-2023

Agata Chrzanowska, Nicola Man, Rachel Sutherland, Louisa Degenhardt and Amy Peacock

Appendix A

Table A1. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by selected drugs and sex

Drug & Sex	Number	Age-standardis	sed rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
All drugs				
Female	25673	201 (198, 203)	216 (213, 219)	-7.1 (-8.7, -5.5)
Male	25686	200 (197, 202)	206 (203, 208)	-3.0 (-4.7, -1.3)
Total	51413	200 (198, 202)	211 (209, 213)	-5.1 (-6.3, -4.0)
Opioids				
Female	2290	17 (16, 17)	18 (18, 19)	-9.5 (-14.6, -4.1)
Male	3155	24 (23, 25)	25 (25, 26)	-6.1 (-10.6, -1.3)
Total	5447	20 (20, 21)	22 (21, 23)	-7.4 (-10.9, -3.9)
GHB				
Female	1042	8.2 (7.7, 8.7)	4.7 (4.3, 5.1)	74 (57, 93)
Male	1073	8.4 (7.9, 9.0)	4.7 (4.4, 5.1)	78 (61, 97)
Total	2119	8.3 (8.0, 8.7)	4.7 (4.4, 5.0)	77 (64, 90)
Cannabinoids				
Female	2599	21 (20, 21)	21 (20, 22)	-1.9 (-7.1, 3.6)
Male	3700	29 (28, 30)	33 (32, 34)	-13 (-17, -9)
Total	6304	25 (24, 25)	27 (26, 28)	-8.8 (-11.9, -5.6)
Cocaine				
Female	198	1.6 (1.3, 1.8)	2.9 (2.6, 3.3)	-47 (-55, -37)
Male	758	6.0 (5.6, 6.5)	7.1 (6.6, 7.6)	-15 (-23, -6)
Total	956	3.8 (3.5, 4.0)	5.0 (4.7, 5.3)	-24 (-31, -18)
Amphetamine-ty	pe stimulants			
Female	4977	39 (38, 41)	36 (35, 37)	11 (7, 16)
Male	8073	64 (63, 65)	60 (58, 61)	7.1 (3.7, 10.5)
Total	13059	52 (51, 53)	48 (47, 48)	8.5 (5.9, 11.3)

Table A2. Crude rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by selected drugs and age group

Drug & Ago	Number	Crudo ra	2022-23 versus 2021-22	
Drug & Age	2022-23	2022-23	te (95% CI) 2021-22	
All drugs	2022-23	2022-23	2021-22	APC (95% CI)
All drugs 10-19	6810	209 (204, 214)	252 (246, 257)	-17 (-20, -14)
20-29	13272	363 (357, 369)		-17 (-20, -14)
30-39	12756	325 (319, 331)	406 (399, 413) 322 (317, 328)	0.83 (-1.64, 3.37)
	8961	264 (258, 269)		
40-49			256 (250, 261)	3.2 (0.1, 6.3)
50-59	4926	154 (149, 158)	154 (150, 158)	-0.16 (-4.05, 3.88)
60-69	2251	79 (76, 82)	76 (73, 79)	4.1 (-1.9, 10.5)
70 and over	1901	59 (56, 62)	61 (59, 64)	-4.1 (-10.0, 2.2)
Opioids	150	40 (41 57)	C 0 (F 0 7 0)	20 / 42 12)
10-19	158	4.8 (4.1, 5.7)	6.8 (5.9, 7.8)	-29 (-42, -12)
20-29	953	26 (24, 28)	29 (27, 31)	-11 (-18, -2)
30-39	1248	32 (30, 34)	32 (30, 33)	0.68 (-7.06, 9.06)
40-49	1132	33 (31, 35)	38 (36, 41)	-13 (-20, -6)
50-59	901	28 (26, 30)	30 (28, 31)	-4.8 (-13.2, 4.4)
60-69	550	19 (18, 21)	17 (15, 19)	14 (1, 29)
70 and over	470	15 (13, 16)	16 (14, 17)	-7.7 (-18.8, 5.0)
GHB		2.5 (2.2.2.4)	2.2 (4.5.2.5)	24 (44 72)
10-19	81	2.5 (2.0, 3.1)	2.0 (1.6, 2.6)	21 (-14, 70)
20-29	784	21 (20, 23)	13 (12, 14)	67 (49, 88)
30-39	820	21 (19, 22)	11 (10, 12)	89 (68, 113)
40-49	322	9.5 (8.5, 10.6)	5.3 (4.6, 6.2)	78 (48, 115)
50-59	96	3.0 (2.4, 3.7)	1.1 (0.7, 1.5)	181 (88, 328)
70 and over	7	0.22 (0.09, 0.45)	0.19 (0.07, 0.42)	13 (-67, 307)
Cannabinoids				
10-19	796	24 (23, 26)	28 (26, 30)	-13 (-21, -4)
20-29	2540	69 (67, 72)	78 (75, 81)	-11 (-16, -6)
30-39	1550	39 (38, 41)	40 (38, 42)	-1.0 (-7.9, 6.3)
40-49	784	23 (21, 25)	25 (23, 27)	-8.3 (-16.9, 1.2)
50-59	444	14 (13, 15)	16 (15, 18)	-14 (-25, -2)
60-69	118	4.1 (3.4, 5.0)	5.4 (4.6, 6.4)	-24 (-41, -2)
70 and over	42	1.3 (0.9, 1.8)	1.1 (0.8, 1.5)	20 (-26, 94)
Cocaine				
10-19	28	0.86 (0.57, 1.24)	1.4 (1.1, 1.9)	-41 (-64, -3)
20-29	272	7.4 (6.6, 8.4)	11 (10, 13)	-34 (-44, -23)
30-39	388	9.9 (8.9, 10.9)	14 (12, 15)	-27 (-36, -17)
40-49	211	6.2 (5.4, 7.1)	6.2 (5.3, 7.1)	0.79 (-17.23, 22.76)
50-59	52	1.6 (1.2, 2.1)	2.0 (1.5, 2.6)	-19 (-45, 18)
Amphetamine-type s	timulants			
10-19	574	18 (16, 19)	20 (19, 22)	-13 (-23, -3)
20-29	3377	92 (89, 96)	97 (94, 101)	-4.9 (-9.4, -0.3)
30-39	4733	121 (117, 124)	115 (112, 119)	4.7 (0.5, 9.1)
40-49	3106	91 (88, 95)	73 (70, 76)	26 (19, 33)
50-59	1042	32 (31, 35)	21 (20, 23)	53 (39, 69)

60-69	149	5.2 (4.4, 6.1)	3.2 (2.6, 4.0)	63 (24, 114)
70 and over	17	0.53 (0.31, 0.84)	0.58 (0.34, 0.91)	-8.5 (-55.7, 88.1)

Note: 95% confidence intervals for the crude rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for the 0-9 years age group are not presented due to sensitivity of the data. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A3. Crude rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by sex and age group

Sex & Age	Number	Crude r	ate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Female				
10-19	4967	314 (305, 322)	377 (368, 387)	-17 (-20, -14)
20-29	6429	360 (352, 369)	405 (396, 415)	-11 (-14, -8)
30-39	5411	273 (266, 281)	265 (258, 272)	3.2 (-0.7, 7.2)
40-49	3889	227 (219, 234)	224 (217, 231)	1.1 (-3.3, 5.8)
50-59	2431	149 (143, 155)	158 (152, 164)	-5.5 (-10.7, -0.1)
60-69	1203	82 (77, 87)	81 (77, 86)	0.49 (-7.35, 9.00)
70 and over	1106	64 (60, 67)	68 (64, 72)	-6.0 (-13.5, 2.2)
Male				
10-19	1826	109 (104, 114)	131 (126, 137)	-17 (-22, -12)
20-29	6817	364 (356, 373)	404 (395, 414)	-9.9 (-12.9, -6.9)
30-39	7337	377 (368, 386)	380 (371, 389)	-0.88 (-4.07, 2.41)
40-49	5070	302 (293, 310)	288 (280, 296)	4.8 (0.7, 9.1)
50-59	2495	158 (152, 165)	150 (144, 156)	5.8 (-0.0, 12.0)
60-69	1048	76 (72, 81)	70 (66, 75)	8.5 (-0.7, 18.6)
70 and over	795	53 (50, 57)	54 (50, 58)	-1.4 (-10.7, 9.0)

Note: 95% confidence intervals for the crude rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for the 0-9 years age group are not presented due to sensitivity of the data. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A4. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by remoteness area of usual residence and by sex

Remoteness & Sex	Number	Age-standard	lised rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Major Cities				
Female	18091	189 (186, 192)	205 (202, 208)	-7.9 (-9.8, -6.0)
Male	18806	195 (192, 198)	203 (200, 206)	-4.0 (-6.0, -2.1)
Total	36942	192 (190, 194)	204 (202, 206)	-6.1 (-7.4, -4.7)
Inner Regional				
Female	3941	192 (186, 198)	211 (205, 218)	-9.0 (-12.9, -4.9)
Male	3309	165 (159, 171)	165 (160, 171)	-0.13 (-4.93, 4.92)
Total	7254	178 (174, 182)	188 (183, 192)	-5.0 (-8.1, -1.8)
Outer Regional				
Female	2444	265 (255, 276)	262 (251, 273)	1.3 (-4.3, 7.3)
Male	1844	197 (188, 206)	209 (199, 218)	-5.5 (-11.5, 0.8)

Total	4289	230 (223, 237)	235 (228, 242)	-2.0 (-6.1, 2.3)
Remote and Very Remote				
Female	576	247 (227, 268)	262 (241, 284)	-5.7 (-15.9, 5.8)
Male	615	245 (226, 266)	223 (204, 242)	10 (-2, 24)
Total	1193	247 (233, 261)	241 (227, 255)	2.3 (-5.7, 11.0)

Table A5. Crude rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by remoteness area of usual residence and by age group

Remoteness &	Number	Crude rat	te (95% CI)	2022-23 versus 2021-22
Age	2022-23	2022-23	2021-22	APC (95% CI)
Major Cities				
10-19	4524	193 (187, 198)	232 (226, 239)	-17 (-20, -14)
20-29	9688	338 (331, 344)	390 (383, 398)	-14 (-16, -11)
30-39	9429	311 (305, 317)	315 (309, 322)	-1.3 (-4.1, 1.6)
40-49	6523	256 (250, 262)	252 (245, 258)	1.8 (-1.7, 5.4)
50-59	3587	159 (154, 164)	155 (150, 160)	2.7 (-2.0, 7.6)
60-69	1554	83 (79, 87)	77 (73, 81)	8.2 (0.6, 16.4)
70 and over	1298	61 (57, 64)	63 (59, 66)	-3.0 (-10.3, 4.8)
Inner Regional				
10-19	1240	210 (198, 222)	257 (244, 270)	-18 (-24, -12)
20-29	1733	356 (339, 373)	378 (361, 396)	-5.9 (-12.0, 0.5)
30-39	1501	271 (257, 285)	265 (251, 279)	2.3 (-4.9, 10.0)
40-49	1181	219 (207, 232)	203 (191, 215)	8.0 (-0.6, 17.4)
50-59	697	116 (107, 125)	127 (118, 137)	-9.2 (-18.1, 0.8)
60-69	424	67 (61, 74)	75 (69, 82)	-11 (-22, 1)
70 and over	381	51 (46, 56)	51 (46, 57)	0.08 (-13.51, 15.81)
Outer Regional				
10-19	749	282 (262, 303)	340 (318, 363)	-17 (-25, -8)
20-29	1042	451 (424, 479)	430 (404, 458)	4.8 (-4.1, 14.4)
30-39	943	363 (340, 387)	342 (319, 365)	6.3 (-3.1, 16.7)
40-49	662	270 (249, 291)	278 (258, 300)	-3.2 (-13.1, 7.9)
50-59	422	150 (136, 165)	164 (149, 179)	-8.3 (-19.8, 4.9)
60-69	211	73 (64, 84)	68 (58, 78)	8.3 (-11.4, 32.4)
70 and over	189	62 (53, 71)	67 (58, 77)	-8.5 (-25.4, 12.3)
Remote and Very Re	mote			
10-19	218	347 (303, 396)	405 (356, 459)	-14 (-29, 3)
20-29	327	487 (435, 542)	501 (449, 557)	-2.8 (-16.8, 13.5)
30-39	309	391 (349, 437)	310 (272, 352)	26 (6, 50)
40-49	179	287 (247, 333)	227 (191, 267)	27 (1, 59)
50-59	87	136 (109, 168)	153 (124, 186)	-11 (-34, 20)
60-69	38	70 (49, 96)	71 (50, 98)	-2.0 (-39.2, 57.8)
70 and over	13	30 (16, 52)	58 (37, 87)	-48 (-76, 6)

Note: 95% confidence intervals for the crude rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for the 0-9 years age group are not presented due to sensitivity of the data. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A6. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by mental and behavioural disorder due to substance use identified in the principal diagnosis, and by sex

Principal	Number	Age-standa	dised rate (95% CI)	2022-23 versus 2021-22
diagnosis & Sex	2022-23	2022-23	2021-22	APC (95% CI)
Any mental and beha	vioural disorder	due to substance us	e	
Female	10675	83 (82, 85)	82 (80, 83)	2.1 (-0.6, 5.0)
Male	17091	134 (132, 136)	136 (134, 139)	-1.8 (-3.9, 0.3)
Total	27780	109 (107, 110)	109 (108, 110)	-0.34 (-2.00, 1.35)
Acute intoxication				
Female	1178	9.3 (8.8, 9.8)	8.5 (8.0, 9.0)	9.7 (0.9, 19.3)
Male	1788	14 (13, 15)	14 (13, 14)	2.6 (-4.0, 9.6)
Total	2968	12 (11, 12)	11 (11, 12)	5.2 (-0.1, 10.8)
Harmful use				
Female	1372	11 (10, 11)	12 (11, 13)	-11 (-17, -4)
Male	2032	16 (15, 17)	17 (16, 17)	-4.4 (-10.1, 1.6)
Total	3408	13 (13, 14)	14 (14, 15)	-6.8 (-11.1, -2.3)
Dependence				
Female	3247	25 (24, 26)	26 (25, 27)	-2.7 (-7.3, 2.2)
Male	5537	43 (42, 45)	48 (47, 50)	-10 (-14, -7)
Total	8785	34 (34, 35)	37 (36, 38)	-7.7 (-10.4, -5.0)
Withdrawal				
Female	914	6.9 (6.5, 7.4)	7.2 (6.8, 7.7)	-4.1 (-12.6, 5.1)
Male	1060	8.2 (7.7, 8.7)	8.1 (7.7, 8.7)	0.65 (-7.68, 9.73)
Total	1975	7.6 (7.2, 7.9)	7.7 (7.4, 8.0)	-1.6 (-7.7, 4.8)
Psychotic disorder				
Female	3804	30 (29, 31)	27 (26, 28)	11 (6, 16)
Male	6489	51 (50, 52)	48 (47, 49)	6.1 (2.4, 9.9)
Total	10299	41 (40, 41)	38 (37, 38)	7.7 (4.7, 10.8)
Other mental and be	havioural disorde	r due to substance	use	
Female	160	1.2 (1.0, 1.4)	0.99 (0.82, 1.18)	23 (-3, 56)
Male	185	1.5 (1.3, 1.7)	1.5 (1.2, 1.7)	0.22 (-18.45, 23.17)
Total	345	1.3 (1.2, 1.5)	1.2 (1.1, 1.4)	9.4 (-6.3, 27.8)

Table A7. Crude rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by mental and behavioural disorder due to substance use identified in the principal diagnosis, and by age

Principal diagnosis & Number Cru	ide rate (95% CI) 2022-23 versus 2021-22
Age 2022-23 2022-23	2021-22 APC (95% CI)
Any mental and behavioural disorder due to substance	
10-19 1487 46 (43, 48)	53 (50, 56) -14 (-20, -8)
20-29 8188 224 (219, 229)	
30-39 8893 227 (222, 231)	
40-49 5721 168 (164, 173)	
50-59 2451 76 (73, 80)	69 (66, 72) 11 (5, 18)
60-69 749 26 (24, 28)	23 (22, 25) 12 (1, 25)
70 and over 283 8.8 (7.8, 9.8)	9.7 (8.7, 10.9) -9.8 (-23.6, 6.4)
Acute intoxication	
10-19 188 5.8 (5.0, 6.6)	8.0 (7.1, 9.1) -28 (-41, -13)
20-29 834 23 (21, 24)	24 (22, 26) -5.1 (-13.9, 4.6)
30-39 975 25 (23, 26)	22 (20, 23) 15 (5, 26)
40-49 654 19 (18, 21)	17 (15, 18) 16 (3, 30)
50-59 229 7.1 (6.2, 8.1)	5.5 (4.7, 6.4) 29 (6, 58)
60-69 52 1.8 (1.4, 2.4)	1.7 (1.2, 2.2) 8.7 (-28.2, 64.8)
70 and over 33 1.0 (0.7, 1.4)	1.3 (0.9, 1.8) -22 (-52, 26)
Harmful use	
10-19 240 7.3 (6.4, 8.3)	9.1 (8.1, 10.3) -20 (-33, -4)
20-29 1064 29 (27, 31)	30 (28, 32) -3.4 (-11.4, 5.3)
30-39 987 25 (24, 27)	22 (21, 24) 13 (3, 24)
40-49 611 18 (17, 19)	24 (22, 26) -25 (-33, -17)
50-59 319 9.9 (8.9, 11.1)	12 (10, 13) -15 (-27, -0)
60-69 171 6.0 (5.1, 7.0)	5.1 (4.3, 6.0) 18 (-6, 49)
70 and over 16 0.50 (0.28, 0.80	0) 0.54 (0.32, 0.87) -8.8 (-56.9, 91.9)
Dependence	
10-19 289 8.8 (7.9, 9.9)	9.6 (8.5, 10.7) -7.7 (-21.7, 8.8)
20-29 2484 68 (65, 71)	79 (76, 82) -14 (-19, -10)
30-39 2801 71 (69, 74)	86 (83, 89) -17 (-21, -13)
40-49 1890 56 (53, 58)	51 (49, 54) 8.5 (1.6, 15.9)
50-59 957 30 (28, 32)	27 (25, 29) 11 (1, 22)
60-69 276 9.7 (8.6, 10.9)	8.8 (7.7, 10.0) 10 (-8, 31)
70 and over 88 2.7 (2.2, 3.4)	3.1 (2.5, 3.8) -13 (-36, 17)
Withdrawal	
10-19 102 3.1 (2.5, 3.8)	3.7 (3.0, 4.4) -15 (-35, 12)
20-29 517 14 (13, 15)	16 (15, 17) -11 (-21, 0)
30-39 523 13 (12, 15)	13 (12, 15) -0.48 (-12.08, 12.65)
40-49 413 12 (11, 13)	11 (10, 12) 13 (-2, 30)
50-59 194 6.0 (5.2, 7.0)	6.6 (5.7, 7.5) -8.1 (-24.8, 12.2)
60-69 108 3.8 (3.1, 4.6)	3.1 (2.5, 3.8) 23 (-8, 66)
70 and over 114 3.5 (2.9, 4.2)	3.4 (2.7, 4.1) 5.2 (-20.0, 38.4)
Psychotic disorder	
10-19 648 20 (18, 21)	22 (20, 23) -8.0 (-17.5, 2.6)

20-29	3193	87 (84, 90)	91 (87, 94)	-3.6 (-8.3, 1.3)
30-39	3523	90 (87, 93)	79 (76, 82)	14 (9, 20)
40-49	2072	61 (58, 64)	51 (48, 53)	20 (12, 28)
50-59	716	22 (21, 24)	18 (16, 19)	25 (12, 39)
60-69	117	4.1 (3.4, 4.9)	4.7 (3.9, 5.6)	-12 (-32, 13)
70 and over	29	0.90 (0.60, 1.29)	1.3 (1.0, 1.8)	-33 (-60, 10)

Note: 95% confidence intervals for the crude rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other mental and behavioural disorder due to substance use identified in the principal diagnosis are not presented due to small numbers. The estimates for the 0-9 years age group are not presented due to sensitivity of the data. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A8. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by mental and behavioural disorder due to substance use identified in the principal diagnosis, and by remoteness area

Principal diagnosis &	Number	Age-standardi	sed rate (95% CI)	2022-23 versus 2021-22
Remoteness	2022-23	2022-23	2021-22	APC (95% CI)
Any mental and behavioural d	isorder due to	substance use		
Major Cities	20624	106 (105, 108)	109 (108, 111)	-2.8 (-4.7, -0.9)
Inner Regional	3405	89 (86, 92)	81 (78, 84)	9.4 (4.1, 14.9)
Outer Regional	1810	103 (98, 108)	101 (96, 105)	2.2 (-4.4, 9.1)
Remote and Very Remote	725	151 (140, 162)	125 (116, 136)	20 (8, 34)
Acute intoxication				
Major Cities	2208	11 (11, 12)	11 (11, 12)	4.0 (-2.1, 10.5)
Inner Regional	229	5.9 (5.2, 6.8)	5.0 (4.3, 5.7)	19 (-2, 45)
Outer Regional	156	8.8 (7.5, 10.3)	9.4 (8.0, 11.0)	-6.4 (-24.9, 16.7)
Remote and Very Remote	60	12 (9, 16)	9.9 (7.3, 13.2)	25 (-15, 83)
Harmful use				
Major Cities	2530	13 (12, 14)	14 (14, 15)	-8.3 (-13.2, -3.2)
Inner Regional	410	10 (9, 12)	12 (11, 14)	-16 (-26, -4)
Outer Regional	245	14 (13, 16)	13 (11, 15)	9.4 (-8.7, 31.1)
Remote and Very Remote	79	17 (13, 21)	15 (12, 19)	12 (-19, 54)
Dependence				
Major Cities	7561	39 (38, 40)	44 (43, 45)	-11 (-13, -8)
Inner Regional	906	23 (22, 25)	18 (17, 20)	27 (15, 40)
Outer Regional	201	11 (9, 13)	11 (9, 13)	0.15 (-17.92, 22.20)
Remote and Very Remote	22	4.6 (2.9, 7.0)	4.6 (2.9, 7.0)	-0.94 (-45.02, 78.48)
Withdrawal				
Major Cities	1285	6.5 (6.2, 6.9)	6.6 (6.2, 7.0)	-0.79 (-8.26, 7.29)
Inner Regional	319	7.8 (6.9, 8.7)	7.2 (6.3, 8.1)	8.2 (-8.0, 27.4)
Outer Regional	245	13 (12, 15)	14 (12, 16)	-5.3 (-20.7, 13.1)
Remote and Very Remote	61	13 (10, 16)	18 (14, 22)	-28 (-48, 1)
Psychotic disorder				
Major Cities	6808	35 (34, 36)	33 (32, 34)	6.9 (3.3, 10.6)
Inner Regional	1490	40 (38, 42)	37 (35, 39)	7.6 (-0.1, 15.8)
Outer Regional	935	54 (50, 57)	52 (48, 55)	4.4 (-4.8, 14.5)
Remote and Very Remote	490	102 (93, 111)	76 (69, 85)	33 (16, 52)
Other mental and behavioural	disorder due	to substance use		

Major Cities	232	1.2 (1.0, 1.4)	1.1 (0.9, 1.3)	9.1 (-9.7, 31.9)
Inner Regional	51	1.4 (1.0, 1.8)	1.1 (0.8, 1.5)	22 (-19, 85)
Outer Regional	28	1.6 (1.1, 2.4)	1.6 (1.1, 2.3)	0.54 (-40.55, 70.01)
Remote and Very Remote	13	2.7 (1.4, 4.6)	_	-

Note: 95% confidence intervals for the age-standardised rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other mental and behavioural disorder due to substance use identified in the principal diagnosis are not presented due to small numbers. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A9. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by external cause of poisoning, and by sex

External cause & Sex	Number	_	ised rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Any drug poisoning				
Female	14982	117 (115, 119)	134 (132, 136)	-13 (-15, -11)
Male	8550	65 (64, 67)	69 (68, 71)	-5.7 (-8.5, -2.8)
Total	23572	91 (90, 92)	101 (100, 103)	-10 (-12, -9)
Unintentional				
Female	2312	17 (16, 18)	18 (18, 19)	-7.5 (-12.7, -2.0)
Male	2581	20 (19, 20)	19 (18, 20)	2.1 (-3.5, 7.9)
Total	4894	18 (18, 19)	19 (18, 19)	-2.7 (-6.5, 1.3)
Intentional				
Female	11735	93 (91, 95)	109 (107, 111)	-14 (-16, -12)
Male	4914	38 (36, 39)	41 (40, 42)	-8.7 (-12.3, -5.1)
Total	16682	65 (64, 66)	75 (74, 76)	-13 (-15, -11)
Undetermined				
Female	753	5.8 (5.4, 6.2)	6.0 (5.6, 6.5)	-3.9 (-13.2, 6.3)
Male	874	6.8 (6.3, 7.2)	7.5 (7.0, 8.0)	-9.5 (-17.5, -0.7)
Total	1632	6.3 (6.0, 6.6)	6.7 (6.4, 7.1)	-6.9 (-13.0, -0.3)

Note: 95% confidence intervals for the age-standardised rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other external causes of drug poisoning identified in the principal diagnosis are not presented due to small numbers. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A10. Crude rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by external cause of poisoning, and by age

External cause & Age	Number	Crude ra	te (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Any drug poisoning				
10-19	5319	163 (159, 167)	199 (194, 204)	-18 (-21, -15)
20-29	5076	139 (135, 143)	163 (159, 167)	-15 (-18, -11)
30-39	3850	98 (95, 101)	98 (95, 101)	0.25 (-4.19, 4.89)
40-49	3235	95 (92, 99)	100 (97, 104)	-5.0 (-9.5, -0.3)
50-59	2467	77 (74, 80)	85 (82, 88)	-9.3 (-14.2, -4.2)
60-69	1496	53 (50, 55)	52 (50, 55)	0.57 (-6.49, 8.16)
70 and over	1601	50 (47, 52)	51 (49, 54)	-3.2 (-9.7, 3.8)
Unintentional				
10-19	350	11 (10, 12)	14 (12, 15)	-21 (-32, -9)

20-29	858	23 (22, 25)	23 (22, 25)	1.5 (-7.9, 11.9)
30-39	876	22 (21, 24)	18 (17, 20)	22 (10, 35)
40-49	727	21 (20, 23)	20 (19, 22)	4.7 (-5.8, 16.4)
50-59	513	16 (15, 17)	19 (17, 20)	-15 (-25, -5)
60-69	440	15 (14, 17)	15 (14, 17)	0.04 (-12.60, 14.50)
70 and over	631	20 (18, 21)	21 (20, 23)	-7.9 (-17.6, 2.8)
Intentional				
10-19	4764	146 (142, 150)	178 (173, 183)	-18 (-21, -15)
20-29	3807	104 (101, 108)	126 (122, 130)	-17 (-21, -14)
30-39	2533	65 (62, 67)	69 (67, 72)	-6.9 (-11.8, -1.6)
40-49	2150	63 (61, 66)	69 (66, 72)	-8.3 (-13.6, -2.7)
50-59	1707	53 (51, 56)	58 (55, 60)	-7.5 (-13.4, -1.1)
60-69	908	32 (30, 34)	32 (30, 35)	-1.6 (-10.3, 8.0)
70 and over	812	25 (23, 27)	25 (23, 27)	-0.31 (-9.73, 10.09)
Undetermined				
10-19	177	5.4 (4.7, 6.3)	6.6 (5.8, 7.6)	-18 (-33, 0)
20-29	371	10 (9, 11)	12 (11, 13)	-14 (-26, -1)
30-39	401	10 (9, 11)	9.2 (8.2, 10.2)	11 (-4, 29)
40-49	307	9.0 (8.1, 10.1)	9.6 (8.6, 10.7)	-5.8 (-19.7, 10.6)
50-59	189	5.9 (5.1, 6.8)	6.8 (5.9, 7.7)	-13 (-29, 6)
60-69	99	3.5 (2.8, 4.2)	3.5 (2.8, 4.3)	-0.78 (-25.72, 32.55)
70 and over	76	2.4 (1.9, 2.9)	2.8 (2.2, 3.4)	-15 (-39, 16)

Note: 95% confidence intervals for the crude rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other external causes of drug poisoning identified in the principal diagnosis are not presented due to small numbers. The estimates for the 0-9 years age group are not presented due to sensitivity of the data. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A11. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by external cause of poisoning, and by remoteness area

External cause & Remoteness	Number	Age-standardise	ed rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Any drug poisoning				
Major Cities	16280	85 (84, 86)	94 (93, 96)	-9.9 (-11.8, -7.9)
Inner Regional	3836	89 (86, 92)	106 (103, 109)	-16 (-20, -12)
Outer Regional	2472	127 (122, 132)	134 (129, 139)	-5.1 (-10.3, 0.4)
Remote and Very Remote	465	95 (87, 104)	115 (106, 125)	-17 (-27, -6)
Unintentional				
Major Cities	3437	18 (17, 18)	18 (17, 19)	-2.6 (-7.1, 2.2)
Inner Regional	699	15 (14, 16)	16 (15, 18)	-7.2 (-16.7, 3.3)
Outer Regional	468	23 (21, 25)	23 (21, 26)	-2.9 (-14.8, 10.8)
Remote and Very Remote	105	21 (17, 26)	26 (22, 31)	-20 (-38, 4)
Intentional				
Major Cities	11459	60 (59, 62)	69 (68, 70)	-12 (-14, -10)
Inner Regional	2846	67 (65, 70)	83 (80, 86)	-19 (-23, -14)
Outer Regional	1848	96 (92, 101)	104 (99, 108)	-6.9 (-12.8, -0.7)
Remote and Very Remote	310	64 (57, 71)	78 (71, 87)	-19 (-30, -5)
Undetermined				

Major Cities	1147	5.9 (5.6, 6.3)	6.6 (6.2, 7.0)	-10 (-17, -2)
Inner Regional	220	5.3 (4.6, 6.1)	5.5 (4.8, 6.3)	-3.5 (-20.1, 16.6)
Outer Regional	120	6.2 (5.1, 7.4)	5.3 (4.3, 6.4)	17 (-11, 52)
Remote and Very Remote	35	7.1 (4.9, 9.9)	7.3 (5.1, 10.2)	-3.3 (-39.6, 54.9)

Note: 95% confidence intervals for the age-standardised rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other external causes of drug poisoning identified in the principal diagnosis are not presented due to small numbers. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A12. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by drug type identified in the principal diagnosis

	Number	Age-standardis	ed rate (95% CI)	2022-23 versus 2021-22
Drug	2022-23	2022-23	2021-22	APC (95% CI)
Opioids	5447	20 (20, 21)	22 (21, 23)	-7.4 (-10.9, -3.9)
Non-opioid analgesics	6531	26 (25, 27)	29 (29, 30)	-12 (-15, -9)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	8345	32 (31, 32)	31 (31, 32)	0.34 (-2.71, 3.48)
Benzodiazepines	3196	12 (11, 12)	14 (14, 15)	-17 (-21, -13)
GHB	2119	8.3 (8.0, 8.7)	4.7 (4.4, 5.0)	77 (64, 90)
Cannabinoids	6304	25 (24, 25)	27 (26, 28)	-8.8 (-11.9, -5.6)
Hallucinogens	241	0.96 (0.84, 1.09)	1.3 (1.1, 1.4)	-24 (-36, -10)
Cocaine	956	3.8 (3.5, 4.0)	5.0 (4.7, 5.3)	-24 (-31, -18)
Amphetamine-type stimulants	13059	52 (51, 53)	48 (47, 48)	8.5 (5.9, 11.3)
Methamphetamine	10590	42 (41, 43)	38 (37, 39)	9.8 (6.8, 12.9)
MDMA/Ecstasy	305	1.2 (1.1, 1.4)	1.0 (0.92, 1.2)	17 (-1, 39)
Antidepressants	3221	13 (12, 13)	15 (14, 15)	-14 (-18, -10)
Antipsychotics and neuroleptics	3149	15 (14, 15)	16 (16, 17)	-11 (-15, -7)
Volatile solvents	711	2.7 (2.5, 2.9)	2.5 (2.3, 2.7)	6.7 (-4.2, 18.8)
Multiple drug use	3449	13 (13, 14)	15 (15, 16)	-11 (-15, -7)

Table A13. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by drug type identified in the principal diagnosis, and by remoteness area of usual residence

External cause &	Number	Age-standardis	sed rate (95% CI)	2022-23 versus 2021-22
Remoteness	2022-23	2022-23	2021-22	APC (95% CI)
All drugs				
Major Cities	36942	192 (190, 194)	204 (202, 206)	-6.1 (-7.4, -4.7)
Inner Regional	7254	178 (174, 182)	188 (183, 192)	-5.0 (-8.1, -1.8)
Outer Regional	4289	230 (223, 237)	235 (228, 242)	-2.0 (-6.1, 2.3)
Remote and Very Remote	1193	247 (233, 261)	241 (227, 255)	2.3 (-5.7, 11.0)
Opioids				
Major Cities	4115	21 (20, 22)	22 (22, 23)	-7.0 (-11.0, -2.9)
Inner Regional	740	16 (15, 17)	16 (15, 18)	-1.6 (-11.5, 9.5)
Outer Regional	345	16 (14, 18)	18 (16, 20)	-11 (-23, 4)

Remote and Very Remote	45	8.9 (6.5, 11.9)	15 (12, 19)	-40 (-59, -12)
Non-opioid analgesics				
Major Cities	4391	24 (23, 25)	27 (26, 28)	-11 (-15, -8)
Inner Regional	1162	28 (26, 29)	33 (31, 35)	-16 (-22, -9)
Outer Regional	750	39 (36, 42)	41 (38, 44)	-5.2 (-14.4, 4.9)
Remote and Very Remote	174	36 (31, 42)	41 (35, 47)	-11 (-28, 9)
Antiepileptic, sedative-hypnotic a	ınd antiparki	nsonism drugs		
Major Cities	6315	32 (31, 33)	33 (32, 33)	-1.3 (-4.8, 2.2)
Inner Regional	1084	25 (23, 26)	23 (22, 25)	6.3 (-2.8, 16.2)
Outer Regional	526	26 (24, 29)	31 (28, 33)	-14 (-24, -3)
Remote and Very Remote	82	16 (13, 20)	20 (16, 24)	-17 (-39, 11)
Benzodiazepines				
Major Cities	2432	12 (12, 13)	14 (14, 15)	-14 (-19, -9)
Inner Regional	390	8.2 (7.4, 9.1)	12 (11, 13)	-33 (-41, -23)
Outer Regional	269	13 (12, 15)	17 (15, 19)	-21 (-33, -7)
Remote and Very Remote	47	9.3 (6.8, 12.4)	10 (8, 14)	-10 (-40, 34)
GHB				
Major Cities	1708	8.7 (8.3, 9.2)	5.2 (4.9, 5.6)	68 (55, 81)
Inner Regional	161	4.3 (3.7, 5.0)	1.8 (1.4, 2.3)	136 (77, 215)
Outer Regional	32	1.8 (1.3, 2.6)	_	_
Cannabinoids				
Major Cities	4232	22 (21, 22)	25 (24, 26)	-13 (-16, -9)
Inner Regional	939	25 (23, 26)	26 (24, 27)	-3.8 (-12.2, 5.3)
Outer Regional	626	35 (33, 38)	35 (32, 38)	0.81 (-9.88, 12.76)
Remote and Very Remote	394	82 (74, 90)	70 (63, 78)	17 (1, 35)
Hallucinogens				
Major Cities	185	0.97 (0.83, 1.12)	1.3 (1.1, 1.5)	-24 (-38, -8)
Inner Regional	21	0.54 (0.33, 0.83)	1.2 (0.9, 1.6)	-55 (-73, -24)
Outer Regional	20	1.0 (0.6, 1.6)	1.0 (0.6, 1.6)	2.5 (-46.1, 94.8)
Cocaine				
Major Cities	892	4.6 (4.3, 4.9)	6.1 (5.8, 6.5)	-24 (-31, -17)
Inner Regional	33	0.90 (0.62, 1.27)	1.1 (0.8, 1.5)	-19 (-49, 29)
Outer Regional	15	0.85 (0.47, 1.41)	1.3 (0.8, 1.9)	-33 (-65, 29)
Amphetamine-type stimulants				
Major Cities	9372	49 (48, 50)	46 (45, 47)	6.2 (3.1, 9.3)
Inner Regional	1704	46 (44, 48)	38 (36, 40)	20 (12, 29)
Outer Regional	928	54 (50, 57)	49 (45, 52)	11 (1, 22)
Remote and Very Remote	274	57 (50, 64)	42 (37, 49)	34 (12, 60)
Methamphetamine				
Major Cities	7590	39 (39, 40)	37 (36, 38)	6.8 (3.3, 10.3)
Inner Regional	1366	37 (35, 39)	30 (28, 31)	26 (16, 36)
Outer Regional	741	43 (40, 46)	38 (35, 41)	13 (1, 25)
Remote and Very Remote	217	45 (39, 51)	34 (29, 40)	32 (8, 62)
Antidepressants				
Major Cities	2112	11 (11, 12)	13 (12, 13)	-13 (-18, -7)
Inner Regional	583	14 (13, 15)	18 (17, 19)	-22 (-31, -13)
Outer Regional	431	22 (20, 25)	24 (22, 27)	-7.8 (-19.3, 5.4)
		,,	. , ,	(-, -, -,

Remote and Very Remote	68	14 (11, 18)	18 (14, 22)	-20 (-42, 10)
Antipsychotics and neuroleptics				
Major Cities	2161	11 (11, 12)	13 (13, 14)	-16 (-20, -11)
Inner Regional	505	12 (11, 14)	17 (15, 18)	-25 (-33, -16)
Outer Regional	376	20 (18, 23)	20 (18, 22)	0.14 (-13.37, 15.75)
Remote and Very Remote	52	11 (8, 14)	17 (13, 21)	-37 (-56, -11)
Volatile solvents				
Major Cities	448	2.3 (2.1, 2.5)	2.2 (2.0, 2.4)	5.2 (-8.1, 20.4)
Inner Regional	103	2.2 (1.8, 2.7)	2.9 (2.4, 3.5)	-24 (-42, -0)
Outer Regional	105	5.6 (4.6, 6.8)	3.1 (2.4, 4.0)	82 (32, 150)
Remote and Very Remote	43	8.9 (6.4, 12.0)	7.6 (5.4, 10.5)	16 (-25, 81)
Multiple drug use				
Major Cities	2719	14 (13, 15)	16 (15, 16)	-9.9 (-14.5, -5.1)
Inner Regional	380	9.6 (8.6, 10.6)	12 (11, 13)	-19 (-29, -7)
Outer Regional	167	9.3 (7.9, 10.8)	11 (10, 13)	-19 (-34, -0)
Remote and Very Remote	53	11 (8, 15)	9.7 (7.1, 12.9)	16 (-22, 72)

Table A14. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by main drugs (all drugs; opioids; amphetamines and other stimulants; cannabinoids; and cocaine), and mental and behavioural disorder due to substance use identified in the principal diagnosis

Drug & Principal diagnosis	Number	Age-standardis	ed rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Opioids				
Any mental and behavioural	2963	11 (11, 12)	11 (11, 12)	-1.3 (-6.3, 3.9)
disorder due to substance use				
Acute intoxication	215	0.82 (0.71, 0.93)	0.99 (0.87, 1.12)	-17 (-31, -1)
Harmful use	218	0.84 (0.73, 0.96)	0.77 (0.67, 0.89)	8.9 (-10.4, 32.4)
Dependence	1891	7.2 (6.9, 7.6)	7.1 (6.8, 7.4)	1.8 (-4.6, 8.6)
Withdrawal	498	1.9 (1.7, 2.0)	2.0 (1.9, 2.2)	-7.5 (-18.3, 4.7)
Psychotic disorder	128	0.50 (0.42, 0.60)	0.51 (0.43, 0.61)	-2.4 (-23.7, 25.0)
Cannabinoids				
Any mental and behavioural	5928	23 (23, 24)	25 (25, 26)	-8.5 (-11.7, -5.2)
disorder due to substance use				
Acute intoxication	268	1.0 (0.9, 1.2)	1.2 (1.1, 1.4)	-14 (-27, 1)
Harmful use	761	3.0 (2.8, 3.2)	3.0 (2.7, 3.2)	0.79 (-8.99, 11.62)
Dependence	1806	7.0 (6.7, 7.4)	8.7 (8.4, 9.1)	-19 (-24, -14)
Withdrawal	424	1.7 (1.5, 1.8)	1.8 (1.7, 2.0)	-9.6 (-20.8, 3.3)
Psychotic disorder	2598	10 (10, 11)	10 (10, 11)	-1.2 (-6.5, 4.3)
Cocaine				
Any mental and behavioural	848	3.4 (3.1, 3.6)	4.5 (4.3, 4.8)	-26 (-32, -19)
disorder due to substance use				
Acute intoxication	65	0.25 (0.20, 0.32)	0.35 (0.28, 0.44)	-28 (-48, -0)
Harmful use	157	0.61 (0.52, 0.71)	0.39 (0.32, 0.48)	56 (21, 101)
Dependence	516	2.1 (1.9, 2.2)	3.3 (3.0, 3.5)	-37 (-43, -29)

Withdrawal	15	0.06 (0.03, 0.10)	0.05 (0.03, 0.09)	18 (-44, 149)
Psychotic disorder	93	0.37 (0.30, 0.45)	0.45 (0.37, 0.54)	-18 (-38, 8)
Amphetamine-type stimulants				
Any mental and behavioural	12034	48 (47, 48)	44 (43, 44)	8.9 (6.1, 11.8)
disorder due to substance use				
Acute intoxication	1684	6.7 (6.4, 7.0)	6.0 (5.7, 6.3)	11 (4, 19)
Harmful use	1080	4.3 (4.0, 4.5)	4.1 (3.8, 4.3)	4.8 (-3.9, 14.2)
Dependence	2523	10.0 (9.6, 10.4)	9.9 (9.5, 10.3)	0.24 (-5.19, 5.98)
Withdrawal	498	2.0 (1.8, 2.2)	1.8 (1.7, 2.0)	8.3 (-4.7, 23.1)
Psychotic disorder	6111	24 (24, 25)	21 (21, 22)	13 (9, 17)

Note: 95% confidence intervals for the age-standardised rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. Data on other mental and behavioural disorder due to substance use identified in the principal diagnosis are not presented due to small numbers. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A15. Age-standardised rate per 100,000 people of drug-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by main drugs (all drugs; opioids; amphetamines and other stimulants; cannabinoids; and cocaine), and external cause of poisoning

Drug & External cause	Number	Age-standardi	sed rate (95% CI)	2022-23 versus 2021-22
	2022-23	2022-23	2021-22	APC (95% CI)
Opioids				
Any drug poisoning	2484	9.0 (8.7, 9.4)	10 (10, 11)	-14 (-19, -9)
Unintentional	961	3.4 (3.2, 3.6)	4.1 (3.9, 4.4)	-17 (-24, -10)
Intentional	1193	4.4 (4.1, 4.6)	4.8 (4.5, 5.0)	-7.9 (-15.0, -0.1)
Undetermined	318	1.2 (1.1, 1.3)	1.6 (1.4, 1.8)	-26 (-37, -15)
Cannabinoids				
Any drug poisoning	376	1.4 (1.3, 1.6)	1.7 (1.5, 1.8)	-13 (-24, 0)
Unintentional	216	0.83 (0.72, 0.95)	0.91 (0.79, 1.03)	-9.0 (-24.5, 9.8)
Intentional	43	0.17 (0.12, 0.23)	0.15 (0.10, 0.20)	13 (-28, 75)
Undetermined	114	0.44 (0.36, 0.53)	0.59 (0.50, 0.70)	-26 (-42, -5)
Cocaine				
Any drug poisoning	108	0.42 (0.35, 0.51)	0.49 (0.41, 0.58)	-14 (-33, 12)
Unintentional	51	0.20 (0.15, 0.26)	0.27 (0.20, 0.34)	-26 (-48, 7)
Intentional	28	0.11 (0.07, 0.16)	0.13 (0.09, 0.19)	-19 (-51, 35)
Undetermined	29	0.12 (0.08, 0.17)	0.09 (0.06, 0.14)	30 (-25, 126)
Amphetamine-type stimulan	ts			
Any drug poisoning	1025	4.1 (3.9, 4.4)	3.9 (3.7, 4.2)	4.1 (-4.7, 13.8)
Unintentional	363	1.5 (1.3, 1.6)	1.3 (1.2, 1.5)	11 (-4, 30)
Intentional	433	1.8 (1.6, 1.9)	1.9 (1.7, 2.0)	-5.2 (-17.0, 8.3)
Undetermined	222	0.87 (0.76, 0.99)	0.77 (0.67, 0.89)	13 (-7, 37)

Note: 95% confidence intervals for the age-standardised rate and average percent change are shown in brackets. Please refer to our <u>methods</u> document on 'Presentation of results' for interpretation of average percent change. The estimates for other external causes of drug poisoning identified in the principal diagnosis are not presented due to small numbers. Please also refer to our <u>methods</u> document on 'Scope of the data' and 'Coding of hospitalisations' for specifications of data selected and all exclusions.

Table A16. Age-standardised rate per 100,000 people of opioid poisoning-related hospitalisations in 2022-23 and 2021-22, and average percent change (APC) for difference between 2022-23 and 2021-22, by opioid type identified in the principal diagnosis

	Number	Age-standardise	ed rate (95% CI)	2022-23 versus 2021-22
Drug	2022-23	2022-23	2021-22	APC (95% CI)
Natural and semi-synthetic opioids	1364	4.8 (4.5, 5.1)	5.1 (4.9, 5.4)	-6.6 (-13.4, 0.8)
Heroin	494	1.9 (1.7, 2.1)	2.6 (2.4, 2.8)	-26 (-34, -17)
Synthetic opioids	340	1.2 (1.1, 1.4)	1.5 (1.4, 1.7)	-17 (-28, -4)
Methadone	164	0.61 (0.52, 0.71)	0.73 (0.62, 0.84)	-16 (-32, 4)
Other and unspecified opioids	121	0.45 (0.37, 0.53)	0.55 (0.47, 0.65)	-20 (-37, 3)

Table A17. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Australian Capital Territory by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	161 (150, 173)	152 (141, 164)	6.1 (-4.4, 17.7)
Non-opioid analgesics	39 (33, 46)	34 (29, 41)	13 (-9, 42)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	28 (23, 33)	24 (20, 29)	14 (-12, 46)
Amphetamine-type stimulants	24 (20, 29)	22 (18, 26)	12 (-14, 46)
Antipsychotics and neuroleptics	17 (13, 21)	19 (15, 24)	-11 (-34, 21)
Opioids	17 (14, 21)	18 (14, 22)	-3.5 (-29.1, 31.3)
Antidepressants	16 (12, 20)	15 (12, 19)	4.3 (-25.3, 45.5)
Methamphetamine	15 (12, 19)	14 (11, 18)	7.2 (-23.1, 49.3)
Cannabinoids	11 (9, 15)	11 (8, 15)	1.7 (-30.6, 48.9)
GHB	6.5 (4.5, 9.2)	_	_
Multiple drug use	5.3 (3.5, 7.7)	3.9 (2.3, 6.1)	37 (-24, 146)

Table A18. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in New South Wales by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	192 (189, 195)	208 (204, 211)	-7.5 (-9.5, -5.4)
Amphetamine-type stimulants	56 (54, 58)	52 (50, 53)	8.2 (3.6, 13.0)
Methamphetamine	46 (44, 47)	42 (40, 43)	9.6 (4.5, 15.0)
Cannabinoids	28 (27, 29)	33 (32, 34)	-15 (-20, -10)

Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	26 (25, 27)	27 (26, 28)	-3.2 (-8.8, 2.8)
Opioids	21 (20, 22)	23 (22, 24)	-8.5 (-14.4, -2.2)
Multiple drug use	20 (19, 21)	24 (23, 25)	-19 (-24, -13)
Non-opioid analgesics	16 (15, 17)	19 (18, 20)	-16 (-22, -9)
Antipsychotics and neuroleptics	8.8 (8.2, 9.5)	11 (10, 11)	-17 (-25, -8)
Antidepressants	7.7 (7.1, 8.4)	8.8 (8.1, 9.5)	-12 (-21, -2)
Cocaine	6.3 (5.8, 6.9)	7.7 (7.1, 8.3)	-18 (-27, -8)
GHB	5.9 (5.4, 6.4)	4.2 (3.8, 4.7)	39 (21, 61)
MDMA/Ecstasy	1.9 (1.6, 2.2)	1.4 (1.2, 1.7)	33 (3, 71)
Volatile solvents	1.7 (1.4, 2.0)	1.7 (1.4, 2.0)	-1.1 (-21.6, 24.9)
Hallucinogens	0.64 (0.48, 0.85)	0.86 (0.67, 1.10)	-25 (-48, 8)

Table A19. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Northern Territory by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	324 (303, 347)	302 (281, 324)	7.4 (-2.5, 18.4)
Cannabinoids	134 (120, 149)	108 (96, 121)	24 (6, 45)
Amphetamine-type stimulants	71 (62, 82)	50 (42, 59)	42 (14, 78)
Methamphetamine	58 (49, 68)	41 (34, 50)	40 (10, 79)
Non-opioid analgesics	38 (31, 47)	46 (38, 56)	-17 (-37, 9)
Antidepressants	18 (13, 24)	22 (17, 29)	-22 (-47, 16)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	18 (13, 24)	20 (15, 27)	-10 (-39, 33)
Opioids	16 (12, 22)	20 (15, 27)	-20 (-48, 23)
Antipsychotics and neuroleptics	12 (9, 18)	14 (10, 20)	-13 (-46, 40)
Volatile solvents	12 (8, 17)	7.3 (4.3, 11.5)	65 (-8, 197)

Table A20. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Queensland by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	223 (219, 227)	241 (236, 245)	-7.2 (-9.5, -4.8)
Amphetamine-type stimulants	50 (48, 52)	48 (46, 50)	3.8 (-1.9, 9.8)
Methamphetamine	38 (36, 40)	35 (33, 37)	7.7 (0.9, 15.0)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	36 (34, 37)	39 (37, 41)	-7.6 (-13.2, -1.6)

Non-opioid analgesics	35 (34, 37)	42 (40, 43)	-15 (-20, -9)
Cannabinoids	26 (25, 28)	27 (25, 28)	-2.6 (-9.8, 5.0)
Antidepressants	21 (19, 22)	25 (23, 26)	-16 (-23, -9)
Opioids	21 (20, 23)	24 (23, 25)	-10 (-17, -3)
Antipsychotics and neuroleptics	17 (16, 18)	20 (18, 21)	-14 (-22, -6)
Multiple drug use	10 (9, 11)	10 (10, 11)	-2.6 (-13.6, 9.9)
GHB	6.2 (5.5, 6.9)	2.8 (2.3, 3.3)	125 (84, 175)
Volatile solvents	4.5 (3.9, 5.1)	3.9 (3.4, 4.5)	13 (-6, 37)
Hallucinogens	1.4 (1.1, 1.8)	1.6 (1.3, 2.0)	-14 (-37, 18)
Cocaine	1.4 (1.1, 1.7)	1.5 (1.1, 1.8)	-6.9 (-33.1, 29.5)
MDMA/Ecstasy	0.92 (0.68, 1.22)	1.2 (0.9, 1.6)	-26 (-49, 9)

Table A21. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in South Australia by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	235 (227, 242)	225 (217, 232)	4.5 (-0.1, 9.2)
Amphetamine-type stimulants	72 (68, 77)	54 (50, 58)	34 (23, 46)
Methamphetamine	61 (57, 64)	43 (40, 46)	41 (28, 55)
Non-opioid analgesics	38 (35, 41)	44 (41, 48)	-14 (-22, -4)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	37 (34, 40)	38 (35, 41)	-2.6 (-12.7, 8.8)
Antidepressants	20 (18, 22)	21 (19, 23)	-3.9 (-17.3, 11.8)
Cannabinoids	20 (18, 23)	20 (18, 22)	1.1 (-13.2, 17.8)
Antipsychotics and neuroleptics	18 (16, 20)	21 (19, 23)	-13 (-26, 1)
Opioids	13 (11, 14)	14 (12, 16)	-9.2 (-24.1, 8.6)
Multiple drug use	11 (9, 12)	7.5 (6.2, 8.9)	44 (15, 82)
GHB	10 (9, 12)	5.3 (4.2, 6.5)	97 (52, 156)
Volatile solvents	2.5 (1.8, 3.4)	2.6 (1.9, 3.5)	-3.8 (-36.5, 45.8)
Cocaine	1.3 (0.8, 2.0)	1.4 (0.9, 2.1)	-4.9 (-46.8, 69.9)
Hallucinogens	1.3 (0.8, 1.9)	1.1 (0.7, 1.8)	10 (-41, 106)
MDMA/Ecstasy	1.3 (0.8, 2.0)	0.66 (0.33, 1.19)	101 (-3, 315)

Table A22. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Tasmania by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	188 (177, 201)	179 (167, 191)	5.4 (-3.8, 15.5)
Amphetamine-type stimulants	38 (33, 44)	25 (21, 30)	56 (24, 96)
Non-opioid analgesics	36 (31, 42)	41 (36, 47)	-13 (-29, 6)
Cannabinoids	35 (30, 41)	18 (15, 23)	89 (47, 144)
Methamphetamine	28 (23, 33)	18 (14, 22)	53 (17, 100)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	21 (18, 26)	16 (13, 20)	32 (0, 75)
Antidepressants	16 (13, 20)	18 (15, 23)	-10 (-33, 21)
Antipsychotics and neuroleptics	14 (11, 18)	14 (11, 18)	1.9 (-26.8, 41.9)
Opioids	12 (10, 16)	12 (9, 15)	4.3 (-25.5, 46.1)
Multiple drug use	9.8 (7.2, 13.0)	29 (24, 34)	-66 (-76, -53)
Volatile solvents	3.8 (2.3, 6.0)	3.5 (2.0, 5.6)	10 (-43, 113)

Table A23. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Victoria by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	193 (189, 196)	206 (202, 209)	-6.2 (-8.4, -3.9)
Amphetamine-type stimulants	49 (47, 51)	50 (49, 52)	-3.0 (-7.6, 1.8)
Methamphetamine	41 (40, 43)	43 (42, 45)	-4.4 (-9.3, 0.8)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	36 (35, 38)	33 (31, 34)	11 (5, 18)
Non-opioid analgesics	26 (25, 27)	27 (26, 29)	-5.4 (-11.6, 1.3)
Opioids	24 (23, 25)	25 (24, 26)	-2.9 (-9.4, 3.9)
Cannabinoids	18 (17, 19)	23 (22, 24)	-24 (-29, -18)
GHB	14 (14, 15)	8.7 (8.0, 9.5)	67 (50, 85)
Multiple drug use	11 (10, 12)	10 (10, 11)	7.2 (-3.5, 19.0)
Antipsychotics and neuroleptics	10 (10, 11)	13 (12, 14)	-21 (-29, -12)
Antidepressants	9.9 (9.1, 10.7)	12 (11, 13)	-15 (-24, -6)
Cocaine	5.3 (4.7, 5.9)	8.0 (7.4, 8.8)	-34 (-43, -25)
Volatile solvents	2.3 (2.0, 2.7)	2.2 (1.9, 2.6)	6.3 (-15.2, 33.2)
MDMA/Ecstasy	1.0 (0.8, 1.3)	0.85 (0.64, 1.11)	18 (-17, 69)
Hallucinogens	0.99 (0.76, 1.26)	1.7 (1.4, 2.0)	-41 (-56, -19)

Table A24. Age-standardised rate (per 100,000 people) of drug-related hospitalisations in 2022-23 and average percent change for difference compared to 2021-22, in Western Australia by drug type identified in the principal diagnosis

Drug	Rate in 2022-23 (95% CI)	Rate in 2021-22 (95% CI)	APC (95% CI)
All drugs	169 (165, 174)	173 (168, 178)	-1.9 (-5.8, 2.2)
Amphetamine-type stimulants	43 (40, 45)	33 (31, 35)	29 (18, 41)
Methamphetamine	34 (32, 36)	26 (24, 28)	33 (20, 46)
Antiepileptic, sedative-hypnotic and antiparkinsonism drugs	27 (26, 29)	28 (26, 30)	-3.4 (-12.6, 6.7)
Non-opioid analgesics	24 (22, 26)	27 (25, 29)	-13 (-22, -3)
Cannabinoids	21 (20, 23)	20 (18, 21)	8.5 (-3.7, 22.3)
Opioids	15 (13, 16)	17 (16, 19)	-14 (-24, -2)
Antipsychotics and neuroleptics	13 (12, 14)	16 (14, 17)	-18 (-29, -5)
Multiple drug use	12 (10, 13)	14 (12, 15)	-14 (-26, -1)
Antidepressants	11 (10, 13)	14 (13, 16)	-21 (-32, -8)
GHB	5.1 (4.3, 6.0)	1.7 (1.3, 2.3)	194 (110, 310)
Volatile solvents	2.1 (1.6, 2.7)	2.1 (1.6, 2.8)	-1.1 (-31.3, 42.4)
Hallucinogens	0.81 (0.51, 1.22)	0.88 (0.55, 1.33)	-8.0 (-49.0, 66.2)
MDMA/Ecstasy	0.67 (0.39, 1.05)	0.54 (0.30, 0.91)	23 (-39, 147)
Cocaine	0.47 (0.25, 0.80)	0.46 (0.24, 0.81)	0.98 (-54, 122)